These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 31965064)

  • 1. The importance of exosomal PDL1 in tumour immune evasion.
    Daassi D; Mahoney KM; Freeman GJ
    Nat Rev Immunol; 2020 Apr; 20(4):209-215. PubMed ID: 31965064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
    Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
    J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobody against PDL1.
    Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
    Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
    Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
    Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand 1 signals in cancer cells.
    Kornepati AVR; Vadlamudi RK; Curiel TJ
    Nat Rev Cancer; 2022 Mar; 22(3):174-189. PubMed ID: 35031777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
    Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition.
    Gong C; Milberg O; Wang B; Vicini P; Narwal R; Roskos L; Popel AS
    J R Soc Interface; 2017 Sep; 14(134):. PubMed ID: 28931635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
    Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
    Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
    Havel JJ; Chowell D; Chan TA
    Nat Rev Cancer; 2019 Mar; 19(3):133-150. PubMed ID: 30755690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of PD‑L1 in colorectal cancer (Review).
    Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
    Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
    Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer.
    Tang Y; Zhang P; Wang Y; Wang J; Su M; Wang Y; Zhou L; Zhou J; Xiong W; Zeng Z; Zhou Y; Nie S; Liao Q
    Front Immunol; 2020; 11():604. PubMed ID: 32322256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
    Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
    Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM; Rennert PD; Freeman GJ
    Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.